{"id":275,"date":"2023-06-07T02:10:42","date_gmt":"2023-06-07T00:10:42","guid":{"rendered":"https:\/\/fastllama.pl\/klient\/ibfm\/?page_id=275"},"modified":"2023-06-28T09:13:49","modified_gmt":"2023-06-28T07:13:49","slug":"chronic-myeloid-leukemia-committee-cml","status":"publish","type":"page","link":"https:\/\/fastllama.pl\/klient\/ibfm\/structure\/committees\/chronic-myeloid-leukemia-committee-cml\/","title":{"rendered":"Chronic Myeloid Leukemia Committee\u00a0(CML)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"275\" class=\"elementor elementor-275\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-19e3f31 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"19e3f31\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-856c212\" data-id=\"856c212\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2a8e353 elementor-widget elementor-widget-text-editor\" data-id=\"2a8e353\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.0 - 29-03-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><strong>Committee chair<\/strong><\/p><p><br \/>Fr\u00e9d\u00e9ric Millot; Poitiers University Hospital, France<br \/>Markus Metzler; University Hospital Erlangen, Germany<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-1393764\" data-id=\"1393764\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-aecbf26 elementor-widget elementor-widget-image\" data-id=\"aecbf26\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.0 - 29-03-2023 *\/\n.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=\".svg\"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}<\/style>\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"225\" height=\"225\" src=\"https:\/\/fastllama.pl\/klient\/ibfm\/wp-content\/uploads\/2023\/06\/image5.jpeg\" class=\"attachment-large size-large wp-image-544\" alt=\"\" srcset=\"https:\/\/fastllama.pl\/klient\/ibfm\/wp-content\/uploads\/2023\/06\/image5.jpeg 225w, https:\/\/fastllama.pl\/klient\/ibfm\/wp-content\/uploads\/2023\/06\/image5-150x150.jpeg 150w\" sizes=\"auto, (max-width: 225px) 100vw, 225px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-9736dc0\" data-id=\"9736dc0\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9ec4ec6 elementor-widget elementor-widget-image\" data-id=\"9ec4ec6\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"238\" height=\"300\" src=\"https:\/\/fastllama.pl\/klient\/ibfm\/wp-content\/uploads\/2023\/06\/image6.jpeg\" class=\"attachment-large size-large wp-image-548\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b210214 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b210214\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1d54d51\" data-id=\"1d54d51\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8971b28 elementor-widget elementor-widget-text-editor\" data-id=\"8971b28\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><strong>Abstract<\/strong><br \/>The Mission of the Chronic Myeloid Leukemia group is to improve treatments for children and adolescents with chronic myeloid leukemia<br \/>Our objectives are:<br \/>To facilitate the development of interventional clinical studies and standards in children with CML including all relevant treatment modalities<br \/>To facilitate registries to promote continuity over successive trials <br \/>To facilitate the development of basic and translational research projects in children with hematological malignancies that help to define the therapeutic strategies in patients with CML<br \/>Identify and mentor next generation clinical scientists in the field of myeloproliferative diseases<\/p><p><br \/><strong>Scientific aims<\/strong><br \/>\u2022 Comparison of clinical and molecular signatures in Pediatric and Adult CML<br \/>\u2022 Differentiating CML-BP from CML-like ALL<br \/>\u2022 Identify predictive markers for successful TFR, dose reduction and stopping TKI<br \/>\u2022 Study the genetic predisposition in CML<br \/>\u2022 Understand the mechanism of the influence of TKI on bone growth<\/p><p><strong>Open and completed clinical trials<\/strong><\/p><p>International CML registry<\/p><p>Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.<\/p><p><strong>Clinical trials<\/strong><br \/>Bosutinib Study ITCC-054\/AAML1921<br \/>Ponatinib Paediatric INCB84344-102 Study<br \/>Asciminib CABL001I12201 \u2013 ASC4KIDS<\/p><p><strong>Selected publications (last 5 years)<\/strong><\/p><p>Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, De Moerloose B, Osborn M, Schultz KR, Sedlacek P, Giona F, Zwaan CM, Shimada H, Versluijs B, Millot F, Hijiya N, Suttorp M, Metzler M. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023 Mar;37(3):505-517.<\/p><p><br \/>Salmon M et al. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022 Jul;36(7):1879-1886<\/p><p>White HE et al. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia 2022, 36(7):1834-1842.<\/p><p>Shima H, Kada A, Tanizawa A, et al. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 2022 Aug;69(8):e29699.<\/p><p>Shimada H, Tanizawa A, Kondo T, et al. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents\/Young Adults With CML in the TKI Era. Transplant Cell Ther. 2022 Jul;28(7):376-389. doi: 10.1016\/j.jtct.2022.04.011.<\/p><p>Shima H, Shimada H.\u3000Recent progress in the management of pediatric chronic myeloid leukemia.\u3000Int J Hematol. 2023 Feb;117(2):182-187. doi: 10.1007\/s12185-022-03526-2. Epub 2022 Dec 27.PMID: 36574169<\/p><p>Leung WY et al. Outcome Prediction of Chronic Myeloid Leukemia in Children. Ann Haematol 2022 Aug<\/p><p>Fr\u00e9d\u00e9ric Millot, Meinolf Suttorp, St\u00e9phanie Ragot, Guy Leverger, Jean-Hugues Dalle, Caroline Thomas, Nathalie Cheikh, Brigitte Nelken, Marilyne Poir\u00e9e, Genevi\u00e8ve Plat, Birgitta Versluys, Birgitte Lausen, Marina Borisevich. Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML Cancers 2021, 13, 4102<\/p><p>Gleixner K et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. Am J Cancer Res. 2021 Sep 15;11(9):4470-4484.<\/p><p>Heibl S et al. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1. Hematol Oncol. 2020.<\/p><p>Mughal TI et al. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020.<\/p><p>Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Youn M, Smith SM, Lee AG, Chae HD, Spiteri E, Erdmann J, Galperin I, Jones LM, Donato M, Abidi P, Bittencourt H, Lacayo N, Dahl G, Aftandilian C, Davis KL, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo TA, Eklund E, Gotlib J, Khatri P, Sweet-Cordero EA, Hijiya N, Sakamoto KM. Cancers. 2021 Dec 14;13(24):6263.<\/p><p>Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas. Janeczko-Czarnecka M, Krawczuk-Rybak M, Karpi\u0144ska-Derda I, Nied\u017awiecki M, Musio\u0142 K, \u0106wikli\u0144ska M, Drabko K, Mycko K, Ociepa T, Pawelec K, Januszkiewicz-Lewandowska D, Ussowicz M, Rybka B, Ryczan-Krawczyk R, Ko\u0142tan A, Karolczyk G, Zaucha-Pra\u017cmo A, Badowska W, Ka\u0142wak K. Adv Clin Exp Med. 2018 Jan;27(1):91-98. <\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Committee chair Fr\u00e9d\u00e9ric Millot; Poitiers University Hospital, FranceMarkus Metzler; University Hospital Erlangen, Germany AbstractThe Mission of the Chronic Myeloid Leukemia group is to improve treatments for children and adolescents with chronic myeloid leukemiaOur objectives are:To facilitate the development of interventional clinical studies and standards in children with CML including all relevant treatment modalitiesTo facilitate registries [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":225,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-275","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/pages\/275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/comments?post=275"}],"version-history":[{"count":13,"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/pages\/275\/revisions"}],"predecessor-version":[{"id":581,"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/pages\/275\/revisions\/581"}],"up":[{"embeddable":true,"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/pages\/225"}],"wp:attachment":[{"href":"https:\/\/fastllama.pl\/klient\/ibfm\/wp-json\/wp\/v2\/media?parent=275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}